Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharmaceuticals, Inc. - Common Stock (NQ: MRNS )

0.3184 -0.0016 (-0.50%)
Streaming Delayed Price Updated: 10:39 AM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
From Marinus Pharmaceuticals
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
From Marinus Pharmaceuticals
Via Business Wire
Analyzing Marinus Pharmaceuticals Inc's Short Interest
Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) short percent of float has risen 9.74% since its last report. The company recently reported that it has 1.23 million shares sold short... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million. 
Via Benzinga
Recap: Marinus Pharmaceuticals Q4 Earnings
Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q4 earnings results on Monday, March 21, 2022 at 07:15 AM. Here's what investors need to know about the announcement... 
Via Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Earnings Scheduled For March 21, 2022
Companies Reporting Before The Bell • Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million. •... 
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
Here's Why Marinus Pharmaceuticals Shares Are Moving
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares are trading higher by 25.0% at $10.72 after the company announced the FDA has approved ZTALMY oral suspension for the... 
Via Benzinga
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Preview: Marinus Pharmaceuticals's Earnings
Marinus Pharmaceuticals (NASDAQ:MRNS) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement.... 
Via Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Tenneco Inc. (NYSE: TEN) shares jumped 94.1% to $19.38 after the company announced it will be acquired by Apollo Funds. Tenneco also reported a Q4 loss of $0.11 per share... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Tenneco Inc. (NYSE: TEN) shares surged 93.9% to close at $19.35 on Wednesday after the company announced it will be acquired by Apollo Funds. Tenneco also reported a... 
Via Benzinga
Nervous Markets Rebound As Ukraine Tensions Fade
U.S. President Joe Biden said Russia had started to invade Ukraine and announced steps targeting Russia’s sale of sovereign debt abroad, its elites and a pair of banks. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial... 
Via Benzinga
23 Stocks Moving in Wednesday's Pre-Market Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 64.9% to $2.54 in pre-market trading after gaining around 5% on Tuesday. Roth Capital recently initiated coverage on the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB 
Via Benzinga
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
From Marinus Pharmaceuticals
Via Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.